Sight Sciences Stock Alpha and Beta Analysis
| SGHT Stock | USD 3.99 0.08 2.05% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Sight Sciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Sight Sciences over a specified time horizon. Remember, high Sight Sciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Sight Sciences' market risk premium analysis include:
Beta 3.28 | Alpha (1.14) | Risk 4.01 | Sharpe Ratio (0.16) | Expected Return (0.64) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Sight |
Sight Sciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Sight Sciences market risk premium is the additional return an investor will receive from holding Sight Sciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Sight Sciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Sight Sciences' performance over market.| α | -1.14 | β | 3.28 |
Sight Sciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Sight Sciences' Buy-and-hold return. Our buy-and-hold chart shows how Sight Sciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Sight Sciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Sight Sciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Sight Sciences shares will generate the highest return on investment. By understating and applying Sight Sciences stock market price indicators, traders can identify Sight Sciences position entry and exit signals to maximize returns.
Sight Sciences Return and Market Media
The median price of Sight Sciences for the period between Sun, Sep 1, 2024 and Sat, Nov 30, 2024 is 5.74 with a coefficient of variation of 18.56. The daily time series for the period is distributed with a sample standard deviation of 1.03, arithmetic mean of 5.54, and mean deviation of 0.87. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Jeremy Hayden of 12000 shares of Sight Sciences subject to Rule 16b-3 | 09/16/2024 |
2 | Disposition of 3403 shares by Sam Park of Sight Sciences at 6.08 subject to Rule 16b-3 | 10/01/2024 |
3 | Disposition of 3167 shares by Badawi David of Sight Sciences at 5.986 subject to Rule 16b-3 | 10/02/2024 |
4 | Sight Sciences CFO sells over 61k in company stock | 10/04/2024 |
5 | Disposition of 20734 shares by Matthew Link of Sight Sciences at 5.905 subject to Rule 16b-3 | 10/16/2024 |
6 | Disposition of 21831 shares by Matthew Link of Sight Sciences at 5.609 subject to Rule 16b-3 | 10/21/2024 |
7 | KCK LTD.s Strategic Reduction in NeuroPace Inc Shares | 10/22/2024 |
8 | Acquisition by Sam Park of 6000 shares of Sight Sciences at 1.96 subject to Rule 16b-3 | 10/25/2024 |
9 | Insider Trading | 11/04/2024 |
10 | Sight Sciences Inc Q3 2024 Earnings Report Preview What To Expect | 11/06/2024 |
11 | Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance | 11/07/2024 |
12 | Sight Sciences Inc Q3 2024 Earnings Call Highlights Navigating Challenges with ... | 11/08/2024 |
13 | Acquisition by Manohar Raheja of 96000 shares of Sight Sciences at 4.59 subject to Rule 16b-3 | 11/12/2024 |
14 | Sight Sciences, Inc. Stocks Pounded By 26 percent But Not Lagging Industry On Growth Or Pricing | 11/13/2024 |
15 | Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference | 11/19/2024 |
16 | Disposition of 551802 shares by Encrantz Staffan of Sight Sciences at 3.73 subject to Rule 16b-3 | 11/21/2024 |
17 | Sight sciences EVP Manohar Raheja acquires 7,400 in stock | 11/22/2024 |
18 | Disposition of 2891 shares by Jesse Selnick of Sight Sciences at 12.379 subject to Rule 16b-3 | 11/25/2024 |
About Sight Sciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Sight or other stocks. Alpha measures the amount that position in Sight Sciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 2.57 | 4.6 | 6.86 | 7.21 | Days Of Inventory On Hand | 147.31 | 180.54 | 241.13 | 253.19 |
Sight Sciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Sight Sciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sight Sciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Sight Sciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Sight Sciences. Please utilize our Beneish M Score to check the likelihood of Sight Sciences' management manipulating its earnings.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 11th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Sight Sciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.